This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Muldoon, L. L. Articles by Neuwelt, E. A. Search for Related Content PubMed PubMed Citation Articles by Muldoon, L. L. Articles by Neuwelt, E. A. Social Bookmarking                            What's this?

Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check

Leslie L. Muldoon, Carole Soussain, Kristoph Jahnke, Conrad Johanson, Tali Siegal, Quentin R. Smith, Walter A. Hall, Kullervo Hynynen, Peter D. Senter, David M. Peereboom, Edward A. Neuwelt

From the Departments of Neurology and Medicine, Oregon Health and Science University, and the Veterans Administration Medical Center, Portland, OR; Department of Neurosurgery Research, Brown Medical School, Providence, RI; Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center; Amarillo, TX; University of Minnesota, Department of Neurosurgery, Minneapolis, MN; Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Seattle Genetics, Bothell, WA; Brain Tumor Institute/Solid Tumor Oncology, Cleveland Clinic, Cleveland, OH; Centre René Huguenin, Hématologie, Saint-Cloud, France; and the Gaffin Center for Neuro-Oncology, Hadassah Hebrew University Hospital, Jerusalem, Israel

Address reprint requests to Edward A. Neuwelt, MD, Oregon Health and Science University, Department of Neurology, 3181 SW Sam Jackson Park Rd, L603, Portland, OR 97239-3098; e-mail: neuwelte{at}ohsu.edu

Purpose This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006.

Results Chemotherapeutic regimens in brain tumor therapy have often emerged from empirical clinical studies with retrospective pharmacologic explanations, rather than prospective trials of rational chemotherapeutic approaches. Brain tumors are largely composed of CNS metastases of systemic cancers. Primary brain tumors, such as glioblastoma multiforme or primary CNS lymphomas, are less common. Few of these tumors have well-defined optimal treatment. Brain tumors are protected from systemic chemotherapy by the blood-brain barrier (BBB) and by intrinsic properties of the tumors. Pharmacologic studies of delivery of conventional chemotherapeutics and novel therapeutics showing actual tumor concentrations and biologic effect are lacking.

Conclusion In this article, we review drug delivery across the BBB, as well as blood-tumor and –cerebrospinal fluid (CSF) barriers, and mechanisms to increase drug delivery to CNS and CSF tumors. Because of the difficulty in treating CNS tumors, innovative treatments and alternative delivery techniques involving brain/cord capillaries, choroid plexus, and CSF are needed.

Supported by National Institutes of Health Grant No. NS33618 from the National Institute of Neurological Disorders and Stroke, and a National Institutes of Health Meeting Grant No. 4R13 CA86959-06 through the National Cancer Institute, the National Institute of Neurological Disorders and Stroke, and the National Institute of Deafness and Other Communication Disorders (E.A.N.).

Presented in part at the 12th Annual Blood-Brain Barrier Meeting, March 23-25, 2006, Sunriver Resort, Sunriver, OR.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann. Onc., November 18, 2009; (2009) mdp529v2. [Abstract] [Full Text] [PDF]

				C. Massard, J. Zonierek, M. Gross-Goupil, K. Fizazi, C. Szczylik, and B. Escudier Incidence of brain metastases in renal cell carcinoma treated with sorafenib Ann. Onc., October 22, 2009; (2009) mdp411v1. [Abstract] [Full Text] [PDF]

				L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al. Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509. [Abstract] [Full Text] [PDF]

				C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro-oncol, August 1, 2008; 10(4): 624 - 630. [Abstract] [Full Text] [PDF]

				D. Yin, X. Wang, B. M. Konda, J. M. Ong, J. Hu, M. R. Sacapano, M. K. Ko, A. J. Espinoza, D. K. Irvin, Y. Shu, et al. Increase in Brain Tumor Permeability in Glioma-Bearing Rats with Nitric Oxide Donors Clin. Cancer Res., June 15, 2008; 14(12): 4002 - 4009. [Abstract] [Full Text] [PDF]

				C. Soussain, K. Hoang-Xuan, L. Taillandier, E. Fourme, S. Choquet, F. Witz, O. Casasnovas, B. Dupriez, B. Souleau, A.-L. Taksin, et al. Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire J. Clin. Oncol., May 20, 2008; 26(15): 2512 - 2518. [Abstract] [Full Text] [PDF]

				N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report Blood, February 1, 2008; 111(3): 1085 - 1093. [Abstract] [Full Text] [PDF]